SCHEMBL2354673

SCHEMBL2354673

CCC(=O)Oc1cccc2cc3ccccc3cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
KMT2A Q03164 6/20 0.44
ALDH1A1 P00352 4/20 0.44
GAA P10253 3/20 0.44
HSD17B10 Q99714 3/20 0.44
MAPK1 P28482 2/20 0.44
PGR P06401 1/20 0.44
PTGS1 P23219 1/20 0.44
ELANE P08246 1/20 0.44
KDM4E B2RXH2 3/20 0.44
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
HPGD P15428 2/20 0.42
ALOX15 P16050 1/20 0.42
ESR1 P03372 2/20 0.41
HIF1A Q16665 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28371330 0.98 ACHE (0.44) ACHEL3MBTL1KMT2AALDH1A1GAA
SCHEMBL27920269 0.89 KDM4E (0.47) L3MBTL1KMT2AALDH1A1GAAHSD17B10
SCHEMBL28375363 0.88 KDM4E (0.46) L3MBTL1KMT2AALDH1A1GAAHSD17B10
SCHEMBL28371448 0.85 KDM4E (0.57) L3MBTL1KMT2AALDH1A1GAAHSD17B10
SCHEMBL448000 0.85 ALDH1A1 (0.60) L3MBTL1KMT2AALDH1A1GAAHSD17B10
SCHEMBL29609999 0.85 ALDH1A1 (0.60) L3MBTL1KMT2AALDH1A1GAAHSD17B10
SCHEMBL28375346 0.84 ALOX15 (0.46) L3MBTL1KMT2AALDH1A1GAAHSD17B10
SCHEMBL28324766 0.84 ALDH1A1 (0.44) L3MBTL1KMT2AALDH1A1GAAHSD17B10
SCHEMBL9561631 0.84 KMT2A (0.52) KMT2AALDH1A1MAPK1KDM4ERAB9A
SCHEMBL28376629 0.84 KDM4E (0.56) L3MBTL1KMT2AKDM4EMEN1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103450714-B A kind of conductive graphite flake and preparation method thereof TORAY ADVANCED MATERIALS RESEARCH LABORATORIES (CHINA) CO., LTD. (CN) 2015-11-25 CN claimed
CN-103450714-A Conductive graphite flake and preparation method thereof TORAY ADVANCED MATERIALS RES LAB CHINA CO LTD 2013-12-18 CN claimed
EP-4707308-A2 PREGABALIN IMMUNOASSAYS ARK Diagnostics, Inc. (US) 2026-03-11 EP disclosed
EP-3761036-B1 PREGABALIN IMMUNOASSAYS ARK DIAGNOSTICS INC (US) 2025-11-19 EP disclosed
US-12203938-B2 Levetiracetam immunoassays ARK DIAGNOSTICS, INC. (US) 2025-01-21 US disclosed
US-20240192236-A1 Compounds and Methods for Use in Detecting Gabapentin ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT 2024-06-13 US disclosed
CN-111413849-B Photosensitive composition, preparation method thereof, pattern forming method and application 常州强力先端电子材料有限公司 2024-03-01 CN disclosed
US-11867705-B2 Compounds and methods for use in detecting gabapentin ARK DIAGNOSTICS, INC. (US) 2024-01-09 US disclosed
US-20230417779-A1 Pregabalin Immunoassays ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT 2023-12-28 US disclosed
CN-114207043-B Composition for producing siliceous film having low dielectric constant and method for producing cured film and electronic device using the same 默克专利有限公司 2023-09-15 CN disclosed
CN-109471330-B Photosensitive composition and photopolymerization initiator used therein 东京应化工业株式会社 2023-08-29 CN disclosed
US-20070218486-A1 Immunoassays, Haptens, Immunogens and Antibodies for Anti-HIV Therapeutics ARK DIAGNOSTICS, INC. (US) 2007-09-20 US disclosed
WO-2007103740-A2 IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS ARK DIAGNOSTICS (US) 2007-09-13 WO disclosed
EP-1700122-A2 IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS ARK DIAGNOSTICS (US) 2006-09-13 EP disclosed
US-20050244816-A1 Immunoassays, haptens, immunogens and antibodies for anti-HIV therapeutics ARK DIAGNOSTICS, INC. (US) 2005-11-03 US disclosed
WO-2005062979-A2 IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS ARK DIAGNOSTICS (US) 2005-07-14 WO disclosed
US-20030031655-A1 Methods of light activated release of ligands from endosomes SEQUITUR, INC. (US) 2003-02-13 US disclosed
WO-2002062989-A2 METHODS OF LIGHT ACTIVATED RELEASE 0F LIGANDS FROM ENDOSOMES SEQUITUR, INC. (US) 2002-08-15 WO disclosed
US-4923819-A Time-resolved fluorescence immunoassay CHIMERIX CORPORATION (US) 1990-05-08 US disclosed
WO-1988007670-A2 TIME-RESOLVED FLUORESCENCE APPARATUS AND IMMUNOASSAY CHIMERIX CORPORATION (US) 1988-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030031655-A1 Methods of light activated release of ligands from endosomes LAMP2, PLAUR, CLTB ACHE 3141/4885L3MBTL1 2218/4885KMT2A 4666/4885
US-20240192236-A1 Compounds and Methods for Use in Detecting Gabapentin GABRE, GABRG3, GABRB2 ACHE 344/4885L3MBTL1 2188/4885KMT2A 4771/4885
US-12203938-B2 Levetiracetam immunoassays GABRG1, GABRA6, LY96 ACHE 101/4885L3MBTL1 1773/4885KMT2A 1674/4885
US-20230417779-A1 Pregabalin Immunoassays GABRG3, GABRG1, GABRB2 ACHE 465/4885L3MBTL1 3726/4885KMT2A 4651/4885
US-11867705-B2 Compounds and methods for use in detecting gabapentin GABRE, GABRG3, GABRB2 ACHE 344/4885L3MBTL1 2188/4885KMT2A 4771/4885
US-20050244816-A1 Immunoassays, haptens, immunogens and antibodies for anti-HIV therapeutics CD4, MPI, ME1 ACHE 663/4885L3MBTL1 2680/4885KMT2A 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.